NASDAQ · MYGN
Healthcare · Medical - Diagnostics & Research
$3.88
Up+$0.12 (+2.96%)
Updated Sep 16, 2026, 6:35 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MYGN closed at $3.88 after 20 trading sessions, up 35.19% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $3.795 | $3.98 | $3.695 | $3.88 | 4.68M |
| Sep 14, 2026 | $3.43 | $3.82 | $3.42 | $3.79 | 2.6M |
| Sep 11, 2026 | $3.37 | $3.425 | $3.195 | $3.42 | 2.55M |
| Sep 10, 2026 | $3.14 | $3.365 | $3.06 | $3.36 | 3.94M |
| Sep 9, 2026 | $3.11 | $3.215 | $3.085 | $3.19 | 967K |
| Sep 8, 2026 | $3.18 | $3.215 | $3.105 | $3.18 | 1.19M |
| Sep 4, 2026 | $3.19 | $3.20 | $3.15 | $3.19 | 806.16K |
| Sep 3, 2026 | $3.25 | $3.32 | $3.16 | $3.23 | 959.06K |
| Sep 2, 2026 | $3.16 | $3.35 | $3.16 | $3.23 | 1.35M |
| Sep 1, 2026 | $2.95 | $3.215 | $2.92 | $3.18 | 3.03M |
| Aug 31, 2026 | $3.15 | $3.26 | $3.04 | $3.22 | 1.54M |
| Aug 28, 2026 | $3.15 | $3.20 | $3.07 | $3.16 | 1.43M |
| Aug 27, 2026 | $3.11 | $3.2699 | $3.09 | $3.18 | 1.28M |
| Aug 26, 2026 | $3.18 | $3.19 | $3.085 | $3.12 | 1.29M |
| Aug 25, 2026 | $3.06 | $3.21 | $3.01 | $3.19 | 1.76M |
| Aug 24, 2026 | $3.20 | $3.20 | $3.00 | $3.05 | 1.35M |
| Aug 21, 2026 | $3.22 | $3.255 | $3.12 | $3.20 | 1.28M |
| Aug 20, 2026 | $3.17 | $3.295 | $3.141 | $3.22 | 1.93M |
| Aug 19, 2026 | $2.95 | $3.20 | $2.9225 | $3.19 | 2.19M |
| Aug 18, 2026 | $3.005 | $3.01 | $2.835 | $2.87 | 2.04M |
The latest Smart Investors Daily articles mentioning MYGN.
MYGN research
Company profile and research snapshot.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Neutral | — |
| Sep 1, 2026 | Piper Sandler | Underweight | — |
| Aug 18, 2026 | Stephens & Co. | Equal-Weight | — |
| Aug 3, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 31, 2026 | TD Cowen | Hold | — |
Generated Sep 16, 2026, 5:22 PM
Myriad Genetics gained nearly 5% today as the company reaffirmed its FY2026 revenue guidance, signaling management confidence in its business trajectory. The affirmation came despite the stock being flagged in recent analyst commentary as among unprofitable names warranting further scrutiny, suggesting mixed sentiment from the investment community.
Bottom line: MYGN's 5% rally reflects modest positive sentiment from management's guidance reaffirmation, though the stock remains under scrutiny for its unprofitable operating model. Investors should monitor both revenue execution toward the $770M-$790M target and concrete signs of margin improvement before increasing conviction on the thesis.
Benzinga · Sep 16, 2026
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate.
Yahoo · Sep 15, 2026
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Benzinga · Sep 11, 2026
RH shares jumped 8.2% premarket after EPS beat estimates despite a revenue miss; Oracle and others gained, while OPTT and ZUMZ fell.
Benzinga · Sep 10, 2026
Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after-market session. The company's market cap stands at $11.5 million. Picard Medical (AMEX:PMI) stock moved upwards
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MYGN.
